
Aspira Pathlab & Diagnostics Ltd is Rated Sell
2026-11-19 10:10:57Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 18 May 2026, reflecting a shift from a previous 'Strong Sell' stance. However, the analysis and financial metrics discussed here represent the company’s current position as of 19 November 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trend, and technical outlook.
Read More
Aspira Pathlab & Diagnostics Ltd is Rated Sell
2026-10-31 10:10:03Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 31 October 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.
Read MoreAspira Pathlab Gains 0.95% Despite Sensex Fall: 4 Key Factors Driving the Move
2026-10-03 13:01:26Key Events This Week 28 Sep: Stock surges 5.00% amid broad market weakness 29 Sep: Aspira Pathlab hits new 52-week and all-time high at Rs.143.34 30 Sep: Stock reaches fresh 52-week and all-time high at Rs.149.99 1 Oct: Profit-taking leads to 4.74% decline, closing at Rs.131.25 Week OpenRs.136.52 Week Close<div class=...
Read More
Broad-Based Technical Strength Lifts Aspira Pathlab & Diagnostics Ltd to 52-Week High of Rs 149.99
2026-09-30 09:48:36Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd touched a new 52-week high of Rs 149.99 on 30 Sep 2026, marking a remarkable 130.47% gain over the past year. This milestone comes amid a backdrop of strong technical momentum that has propelled the micro-cap healthcare services stock well ahead of the broader market’s subdued performance.
Read More
Aspira Pathlab & Diagnostics Ltd Hits All-Time High of Rs 149.99 as Momentum Builds Across Timeframes
2026-09-30 09:36:15Extending its winning streak to four sessions, Aspira Pathlab & Diagnostics Ltd surged to a fresh all-time high of Rs 149.99 on 30 Sep 2026, outperforming its healthcare services sector peers and the broader Sensex by a wide margin.
Read More
Aspira Pathlab & Diagnostics Ltd Hits All-Time High of Rs 143.34 as Momentum Builds Across Timeframes
2026-09-29 09:34:52Extending its winning streak to three sessions, Aspira Pathlab & Diagnostics Ltd surged 5% today to touch a fresh all-time high of Rs 143.34, significantly outperforming the Healthcare Services sector and the broader Sensex.
Read More
Aspira Pathlab & Diagnostics Ltd is Rated Sell
2026-09-28 10:10:05Aspira Pathlab & Diagnostics Ltd is rated Sell by MarketsMOJO. This rating was last updated on 18 May 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 28 September 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreAspira Pathlab & Diagnostics Ltd Gains 13.06%: 2 Key Milestones Drive the Rally
2026-09-26 13:01:31Key Events This Week 21 Sep: Stock opens week at Rs.120.75, surging 5.00% 22 Sep: Continues strong gains, closing at Rs.126.78 (+4.99%) 23 Sep: Hits Rs.133.11 (+4.99%), technical bullishness confirmed 24 Sep: Reaches new 52-week and all-time high of Rs.138.99 25 Sep: Week closes at Rs.130.02, marginal gain of 0.04% Week Open <div cla...
Read More
Broad-Based Technical Strength Lifts Aspira Pathlab & Diagnostics Ltd to 52-Week High of Rs 138.99
2026-09-24 09:49:16Surging to a fresh 52-week and all-time high of Rs 138.99 on 24 Sep 2026, Aspira Pathlab & Diagnostics Ltd has demonstrated remarkable price momentum, rallying over 44.5% in just the past 10 trading sessions. This impressive run has propelled the stock well above all key moving averages, underscoring a strong technical foundation amid a broader market environment that remains subdued.
Read MoreDisclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
18-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
14-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
14-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available